Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer Protein

Cat. No. MHC-HM489B

Description

Source	Recombinant Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus.
	It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and CLAVEEVSL peptide.
Accession	A0A140T913(HLA-A*02:01)&P61769(B2M)&CLAVEEVSL
Molecular Weight	The protein has a predicted MW of 50.4 kDa. Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The nucleophosmin (NPM1) mutant protein, a leukemia-associated antigen characterized by its leukemia-restricted expression and immunogenic potential, has emerged as a promising therapeutic target for acute myeloid leukemia (AML) immunotherapy. Among its immunogenic epitopes, the CLAVEEVSL peptide derived from the full C-terminal region of the NPM1-mutated isoform demonstrates potent immunogenicity, making it a prime candidate for T cell-based immunotherapies.

Assay Data

Bis-Tris PAGE



Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer Protein

Cat. No. MHC-HM489B

Assay Data



The purity of Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer is greater than 95% as determined by SEC-HPLC.